Recombinant, modified adenoviral vectors for tumor specific gene expression and uses thereof

US6686196B2 · kind B2 · utility

Assignee

• University of Washington · US

Inventors

• Andre Lieber · Seattle, US
• Dirk S. Steinwaerder · Hamburg, DE
• Cheryl A. Carlson · Seattle, US
• Jie Mi · Seattle, US

Key dates

• Filing date: May 3, 2001
• Grant date: Feb 3, 2004
• Expiry date: Nov 28, 2021

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2840/20
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention provides modified recombinant Ad vectors (e.g., AdE1− vectors) undergoing defined homologous recombination in order to create predictably rearranged genomic derivatives in a host cell. Genomic rearrangements can be achieved, for example, by incorporating two IR sequences within one vector genome and enabling genomic rearrangement by coinfection with two parental vectors of one type (also referred to herein as a one vector system) or by homologous recombination of overlapping regions in two distinct types of parental vectors (with or without IR sequences) and enabling genomic rearrangement only upon coinfection of the host cell with the two distinct parental vectors (also referred to herein as two vector system).